Bio-Rad to Report Third-Quarter 2017 Financial Results Thursday, November 2, 2017
October 13 2017 - 7:28PM
Business Wire
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global
provider of life science research and clinical diagnostic products,
will report financial results for the third quarter 2017 on
Thursday, November 2, 2017, following the close of the market. The
company will discuss these results in a conference call scheduled
for 2 PM Pacific Time (5 PM Eastern Time) that day.
To listen, call 855-779-9068 within the U.S. or 631-485-4862
outside the U.S., Conference ID: 96703879. You may also listen to
the conference call live via a webcast that is available on the
“Investor Relations” section of our website under “Quarterly
Results” at www.bio-rad.com. The webcast will be available for up
to a year.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops,
manufactures, and markets a broad range of innovative products and
solutions for the life science research and clinical diagnostic
markets. The company is renowned for its commitment to quality and
customer service among university and research institutions,
hospitals, public health and commercial laboratories, as well as
the biotechnology, pharmaceutical, and food safety industries.
Founded in 1952, Bio‑Rad is based in Hercules, California, and
serves more than 100,000 research and healthcare industry customers
through its global network of operations. The company employs more
than 8,350 people worldwide and had revenues exceeding $2 billion
in 2016. For more information, please visit www.bio-rad.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171013005714/en/
Investor and Financial Contacts:Bio-Rad Laboratories,
Inc.Christine Tsingos, 510-724-7000Executive Vice President and
Chief Financial OfficerRon Hutton, 510-724-7000Vice President and
Treasurer
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Sep 2023 to Sep 2024